The 340B program has become a flash point in the growing debate over the cost of prescription drugs in the U.S.

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

South African regulators decided Vertex Pharmaceuticals has provided sufficient access to its cystic fibrosis medications, ...

After public health labs in California failed to confirm a positive result, a sample was sent to the CDC, which Thursday said ...

Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Happy birthday to Taylor Swift! She’s now old enough to run for president of the United States (not saying she SHOULD, just ...

HHMI will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for funds to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

SAN DIEGO — Brian Koffman found himself in a situation a couple years ago that most chronic lymphocytic leukemia patients ...